Novartis (NVS) shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting. A total of 1,554 shareholders were present at the meeting held in Basel, representing approximately 59.15% of the issued shares of Novartis. With a dividend increase of 5.7% to CHF 3.70 per share, shareholders approved the 29th consecutive increase, resulting in a dividend yield of 3.0%. Payment of the 2025 dividend will be made from March 12, 2026. Shareholders have re-elected Giovanni Caforio as member of the Board of Directors and Board Chair. In addition, shareholders elected Charles Swanton as new member of the Board of Directors. Daniel Hochstrasser did not stand for re-election. All other members of the Board of Directors have been re-elected.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Best ETFs to Invest In, According to AI Analyst, 3/4/2026
- Trump Trade: U.S. stocks tumble, oil prices surge after strikes on Iran
- Trump says ‘tariffs have influenced’ Novartis to build 7+ facilities
- Atrium Therapeutics launches as newly independent, publicly traded company
- Novartis completes acquisition of Avidity Biosciences